علاج التهاب الكلية الغشائي التكاثري لدى المراهقين من 12 إلى 17 عامًا مع اعتلال الكلية C3 أو IC-MPGN الأولي

References

DOI: 10.1016/j.ekir.2025.10.020

• In 2025, pegcetacoplan was also approved by the US Food and Drug Administration for the treatment of adult and pediatric patients aged $ 12 years with C3G or primary IC-MPGN to reduce proteinuria.
• Adolescents (12–17 yrs old), n (%)
• General supportive care for all patients with glomerular diseases who have edema, proteinuria and/or hypertension
• RAASi (e.g. ACEi or ARBs) and potentially other antiproteinuric agents
• Alternative anti-hypertensives (e.g. CCBs)